Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM

Modern Pathology

Volumn 28, Issue 7, 2015, Pages 977-993

  Griffin, Heather ^a,b   Soneji, Yasmina ^b   Van Baars, Romy ^c   Arora, Rupali ^d   Jenkins, David ^c   Van De Sandt, Miekel ^c   Wu, Zhonglin ^b   Quint, Wim ^c   Jach, Robert ^e   Okon, Krzysztof ^e   Huras, Hubert ^e   Singer, Albert ^d   Doorbar, John ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c DDL DIAGNOSTIC LABORATORY   (Netherlands)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; ONCOGENE PROTEIN E4, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; TUMOR MARKER;

CANCER GRADING; FEMALE; HUMAN; METABOLISM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

BIOMARKERS, TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; NEOPLASM GRADING; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84934440275     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.52     Document Type: Article

References (61)

1. Bosch FX, Broker TR, Forman D et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013;31:I1-31.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
3. Doorbar J, Quint W, Banks L et al. The biology and lifecycle of human papillomaviruses. Vaccine 2012;30: F55-F70.
4. Westra WH. The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head Neck Pathol 2012;6:S48-S54.
5. de Villiers EM, Fauquet C, Broker TR et al. Classification of papillomaviruses. Virology 2004;324:17-27.
6. Peh WL, Middleton K, Christensen N et al. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol 2002;76: 10401-10416.
7. Cubie HA. Diseases associated with human papillomavirus infection. Virology 2013;445:21-34.
8. Jenkins D. Histopathology and cytopathology of cervical cancer. Dis Markers 2007;23:199-212.
9. Arwert EN, Hoste E, Watt FM. Epithelial stem cells, wound healing and cancer. Nat Rev Cancer 2012;12: 170-180.
10. Kurman RJ, Ellenson LH, Ronnett BM. Blaustein's Pathology of the Female Genital Tract. Springer: New York, USA, 2010.
11. Pyeon D, Pearce SM, Lank SM et al. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog 2009;5:e1000318.
12. Middleton K, Peh W, Southern S et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 2003;77:10186-10201.
13. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 2011;19:33-39.
14. Isaacson Wechsler E, Wang Q, Roberts I et al. Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression. J Virol 2012;86:6358-6364.
15. Hafner N, Driesch C, Gajda M et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008;27: 1610-1617.
16. Khleif SN, DeGregori J, Yee CL et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996;93:4350-4354.
17. Chen HC, Schiffman M, Lin CY et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011;103:1387-1396.
18. Geraets DT, van Doorn LJ, Kleter B et al. Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections. PLoS One 2013;8:e80382.
19. Quint KD, de Koning MN, Quint WG et al. Progression of cervical low grade squamous intraepithelial lesions: in search of prognostic biomarkers. Eur J Obstet Gynecol Reprod Biol 2013;170:501-506.
20. Cantor SB, Atkinson EN, Cardenas-Turanzas M et al. Natural history of cervical intraepithelial neoplasia: a meta-analysis. Acta Cytol 2005;49:405-415.
21. Doorbar J, Cubie H. Molecular basis for advances in cervical screening. Mol Diagn 2005;9:129-142.
22. Roman A, Munger K. The papillomavirus E7 proteins. Virology 2013;445:138-168.
23. Tornesello ML, Buonaguro L, Giorgi-Rossi P et al. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. BioMed Res Int 2013;2013:519619.
24. von Knebel Doeberitz M, Reuschenbach M, Schmidt D et al. Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics 2012;9:149-163.
25. Ikenberg H, Bergeron C, Schmidt D et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013;105:1550-1557.
26. McLaughlin-Drubin ME, Crum CP, Munger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011;108:2130-2135.
27. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers 2007;23:297-313.
28. Griffin H, Wu Z, Marnane R et al. E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. PLoS One 2012;7:e49974.
29. van der Marel J, van Baars R, Quint W et al. The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis. BJOG 2014;121: 1117-1126.
30. Kleter B, van Doorn LJ, ter Schegget J et al. Novel short-fragment PCR assay for highly sensitive broadspectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-1739.
31. Kleter B, van Doorn LJ, Schrauwen L et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-2517.
32. Quint W, Jenkins D, Molijn A et al. One virus, one lesion-individual components of CIN lesions contain a specific HPV type. J Pathol 2012;227:62-71.
33. Doorbar J, Foo C, Coleman N et al. Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. Virology 1997;238:40-52.
34. de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-1056.
35. Kalantari M, Garcia-Carranca A, Morales-Vazquez CD et al. Laser capture microdissection of cervical human papillomavirus infections: copy number of the virus in cancerous and normal tissue and heterogeneous DNA methylation. Virology 2009;390:261-267.
36. Guan P, Howell-Jones R, Li N et al. Human papillomavirus types in 115, 789 HPV-positive women: a metaanalysis from cervical infection to cancer. Int J Cancer 2012;131:2349-2359.
37. Davy CE, Jackson DJ, Raj K et al. Human papillomavirus type 16 E1-E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/Cyclin B1 complexes. J Virol 2005;79:3998-4011.
38. Carreon JD, Sherman ME, Guillen D et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of populationbased cervical samples. Int J Gynecol Pathol 2007;26: 441-446.
39. Cuzick J, Bergeron C, von Knebel Doeberitz M et al. New technologies and procedures for cervical cancer screening. Vaccine 2012;30:F107-F116.
40. Bulkmans NW, Rozendaal L, Voorhorst FJ et al. Longterm protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005;92:1800-1802.
41. Elfstrom KM, Smelov V, Johansson AL et al. Long-term HPV type-specific risks for ASCUS and LSIL: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer 2014;136:350-359.
42. Ronco G, Dillner J, Elfstrom KM et al. Efficacy of HPVbased screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-532.
43. Kocken M, Uijterwaal MH, de Vries AL et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol 2012;125:500-507.
44. Litjens RJ, Hopman AH, van de Vijver KK et al. Molecular biomarkers in cervical cancer diagnosis: a critical appraisal. Expert Opin Med Diagn 2013;7: 365-377.
45. Maiorano D, Lutzmann M, Mechali M. MCM proteins and DNA replication. Curr Opin Cell Biol 2006;18: 130-136.
46. Murphy N, Ring M, Heffron CC et al. Quantitation of CDC6 and MCM5 mRNA in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Mod Pathol 2005;18:844-849.
47. Murphy N, Ring M, Heffron CC et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol 2005;58:525-534.
48. McCluggage WG, Walsh MY, Thornton CM et al. Inter-and intra-observer variation in the histopathological reporting of cervical squamous intraepithelial lesions using a modified Bethesda grading system. Br J Obstet Gynaecol 1998;105:206-210.
49. Piaton E, Advenier AS, Carre C et al. p16(INK4a)/Ki-67 dual labelling as a marker for the presence of highgrade cancer cells or disease progression in urinary cytopathology. Cytopathology 2013;24:327-334.
50. McIntosh PB, Martin SR, Jackson DJ et al. Structural analysis reveals an amyloid form of the human papillomavirus type 16 E1-E4 protein and provides a molecular basis for its accumulation. J Virol 2008;82: 8196-8203.
51. Khan J, Davy CE, McIntosh PB et al. Role of calpain in the formation of human papillomavirus type 16 E1-E4 amyloid fibers and reorganization of the keratin network. J Virol 2011;85:9984-9997.
52. Wang Q, Kennedy A, Das P et al. Phosphorylation of the human papillomavirus type 16 E1-E4 protein at T57 by ERK triggers a structural change that enhances keratin binding and protein stability. J Virol 2009;83: 3668-3683.
53. Doorbar J. The E4 protein; structure, function and patterns of expression. Virology 2013;445:80-98.
54. Davy C, Doorbar J. G2/M cell cycle arrest in the life cycle of viruses. Virology 2007;368:219-226.
55. Ortoft G, Henriksen T, Hansen E et al. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG 2011;117:258-267.
56. Armarnik S, Sheiner E, Piura B et al. Obstetric outcome following cervical conization. Arch Gynecol Obstet 2011;283:765-769.
57. Kinney W, Hunt WC, Dinkelspiel H et al. Cervical excisional treatment of young women: a populationbased study. Gynecol Oncol 2014;132:628-635.
58. Henderson D, Hall L, Prpic N et al. The selection and characterization of antibodies to minichromosome maintenance proteins that highlight cervical dysplasia. J Immunol Methods 2011;370:1-13.
59. Galgano MT, Castle PE, Atkins KA et al. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010;34: 1077-1087.
60. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-1505.
61. Vrdoljak-Mozetic D, Krasevic M, Versa Ostojic D et al. HPV16 genotype, p16/Ki-67 dual staining and koilocytic morphology as potential predictors of the clinical outcome for cervical low-grade squamous intraepithelial lesions. Cytopathology 2013;26:10-18.